FDA knocks back King Pharmaceuticals self-injectible epilepsy product

King Pharmaceuticals, Inc. has reported the receipt by its Meridian Technologies subsidiary of a letter from the U.S. Food and Drug Administration advising the Company that its Abbreviated New Drug Application (“ANDA”) regarding King’s diazepam-filled auto-injector therapy for the emergency treatment of status epilepticus and severe recurrent convulsive seizures associated with epilepsy is not approvable.

The FDA raised concerns regarding whether the product, a self-injectible therapy, is appropriate for self-diagnosis and use. King is currently evaluating how best to satisfy the concerns raised by the FDA with the intent of amending or resubmitting the application.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Hesperos’ immune system-on-a-chip emulates immune reactions for tissue damage and acute inflammation